RECRUITING

Level of Physical Activity and Fear Learning

Talk to us

Conditions

Generalized Anxiety DisorderSocial Anxiety DisorderPanic Disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed experimental study will be the first to investigate whether exercise vs. sitting enhances consolidation of extinction learning in adults with high AS and anxiety disorders, and the mechanistic pathways of expectancy, affect, and key stress response markers.

Official Title

The Role of Exercise in the Consolidation of Fear Extinction Learning in Adults With High Anxiety Sensitivity

Quick Facts

Study Start:2023-01-31
Study Completion:2025-01-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05203731

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Males and females ages 18-60
  2. * A primary diagnosis of a DSM-5 anxiety disorder (generalized anxiety disorder, panic disorder, social anxiety disorder)
  3. * Anxiety Sensitivity Index-3 score of ≥23 (i.e., high anxiety sensitivity)
  4. * Able and willing to provide informed consent
  1. * Lifetime Bipolar Disorder or psychosis
  2. * Past 3 months substance use disorder or eating disorder
  3. * Current PTSD (past PTSD \> 6 months prior to screening is allowed)
  4. * High risk for exercise according to the Physical Activity Readiness Questionnaire and American College of Sports Medicine guidelines with excluded active medical conditions including heart conditions, lung disease, bone/joint problems, or seizures
  5. * Women who are currently pregnant
  6. * Acute suicide risk (active suicidal ideation with plan and intent) as indicated by a score of ≥4 on the Columbia Suicide Severity Rating Scale (C-SSRS)
  7. * Benzodiazepine use
  8. * Current substance abuse or positive urine toxicology screen (recreational use of marijuana is permitted based on clinical assessment on the MINI structured diagnostic interview that it does not meet criteria for cannabis use disorder)
  9. * Stable psychiatric medications for at least 4 weeks prior to experimental procedures

Contacts and Locations

Study Contact

Kristin Szuhany, MD
CONTACT
646-754-5161
Kristin.szuhany@nyulangone.org
Giselle Corneji
CONTACT
Giselle.Cornejo@nyulangone.org

Principal Investigator

Kristin Szuhany, MD
PRINCIPAL_INVESTIGATOR
NYU Langone Health

Study Locations (Sites)

NYU Langone Health
New York, New York, 10016
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Kristin Szuhany, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-31
Study Completion Date2025-01-14

Study Record Updates

Study Start Date2023-01-31
Study Completion Date2025-01-14

Terms related to this study

Additional Relevant MeSH Terms

  • Generalized Anxiety Disorder
  • Social Anxiety Disorder
  • Panic Disorder